Intellia - רווח נקי למניה (EPS TTM) NTLA

Uncertainty in the emerging gene therapy market creates risks, as confirmed by the current Intellia Therapeutics (NTLA) TTM EPS, which stands at -3.33. The stability of Intellia Therapeutics (NTLA) is ensured by the strategic outsourcing of production and testing to external contractors. Additionally, the company minimizes threats through scientific alliances with biotech leaders to develop innovative treatments for hereditary pathologies.
Intellia (NTLA) - פילוחי מדדים ודוחות פיננסיים

To assess the investment attractiveness of Intellia Therapeutics (NTLA), it is critical to analyze earnings per share (EPS) dynamics, which allows for the determination of the actual return on capital. The rolling annual EPS reflects the final financial result over a 12-month period, confirming the effectiveness of clinical trial cost management while maintaining full control over intellectual property.